January 20, 2012 - The international team of medical experts are calling into question the safety and efficacy of anti-flu drug Tamiflu, oseltamivir article), saying that the review of unpublished data indicates non-compliance and that the drug's manufacturer, Roche, has failed to provide access to a range of information on its content. review was published online January 18, the Cochrane Library. Governments around the world spent billions of dollars stockpiling oseltamivir and zanamivir (Relenza, GlaxoSmithKline) - neuraminidase inhibitor drugs have been recommended by the World Health Organization, 2002. To treat flu pandemic. This class of drugs, data integrity and continues to be debate, however. In a previous Cochrane review published in 2008., Researchers documented a significant concern for publication bias in drug. Importantly, they reported that as much as 60% of patient data from the Phase 3 trials for oseltamivir treatment has never been published. U...